Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Monophosphothiamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | TKT | P29401 | 9/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Monophosphothiamine SCHEMBL29733068 | 0.99 | TDP1 (0.98) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL94443 | 0.99 | TDP1 (0.98) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL399485 | 0.98 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL3681710 | 0.98 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL9159014 | 0.98 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL23151818 | 0.98 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL17768676 | 0.98 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL29373566 | 0.98 | TDP1 (1.00) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL94444 | 0.98 | TDP1 (1.00) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL4302184 | 0.97 | TDP1 (0.94) | TDP1TKTLMNAHSP90AA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5443834-A | Thiamine mixed with beef tallow, coconut oil, perfume and glycerin | FUJI SANGYO KAISHA, LTD. (JP) | 1995-08-22 | — | — | US | claimed |
| EP-0503852-A1 | Soap compounded with vitamin B1-containing garlic extract | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-09-16 | — | — | EP | claimed |
| JP-58021618-A | — | — | None | — | — | JP | disclosed |
| JP-11060487-A | — | — | None | — | — | JP | disclosed |
| WO-2025074120-A1 | NANOPARTICLES FOR EXTENDED RELEASE DRUG DELIVERY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-04-10 | — | — | WO | disclosed |
| US-11564924-B2 | Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound | RENASCIENCE CO., LTD. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-11253519-B2 | Composition used to improve symptoms of autism spectrum disorder, and method using same for improving symptoms of autism spectrum disorder | RENASCIENCE CO., LTD. (JP) | 2022-02-22 | — | — | US | disclosed |
| US-20210000829-A1 | PHARMACEUTICAL COMPOSITION FORMED BY COMBINING PYRIDOXAMINE COMPOUND AND THIAMINE COMPOUND | RENASCIENCE CO., LTD. (JP) | 2021-01-07 | — | — | US | disclosed |
| US-20200368233-A1 | COMPOSITION USED TO IMPROVE SYMPTOMS OF AUTISM SPECTRUM DISORDER, AND METHOD USING SAME FOR IMPROVING SYMPTOMS OF AUTISM SPECTRUM DISORDER | RENASCIENCE CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| US-20190053988-A1 | METHOD FOR PRODUCING CELLULOSE FIBERS SUITABLE FOR USE IN A THICKENING COMPOSITION, METHOD FOR PRODUCING A THICKENING COMPOSITION, AND METHOD FOR THICKENING A COMPOSITION | NISSAN CHEMICAL IND LTD (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3424501-A1 | COMPOSITION USED TO IMPROVE SYMPTOMS OF AUTISM SPECTRUM DISORDER, AND METHOD USING SAME FOR IMPROVING SYMPTOMS OF AUTISM SPECTRUM DISORDER | Tohoku University (JP) | 2019-01-09 | — | — | EP | disclosed |
| EP-1262173-B1 | Oral intake solution comprising reduced water | NIHON TRIM CO LTD (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-20030045502-A1 | Oral intake solution | NIHON TRIM CO., LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
| EP-1262173-A1 | Oral intake solution comprising reduced water | Nihon Trim Co. Limited (JP) | 2002-12-04 | — | — | EP | disclosed |
| US-20020099032-A1 | Preparations and method of producing the same | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| CN-1258503-A | Vitamine preparation | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-07-05 | — | — | CN | disclosed |
| JP-H1160487-A | VITAMIN B1 DERIVATIVE-FORMULATED SOLUTION | TAISHO PHARMACEUT CO LTD | 1999-03-02 | — | — | JP | disclosed |
| US-5443834-A | Thiamine mixed with beef tallow, coconut oil, perfume and glycerin | FUJI SANGYO KAISHA, LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| EP-0503852-A1 | Soap compounded with vitamin B1-containing garlic extract | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-09-16 | — | — | EP | disclosed |
| JP-S5821618-A | IMMUNOREGULATOR COMPOSED OF VITAMIN B COMPOSITION | SANKYO CO LTD | 1983-02-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000829-A1 | PHARMACEUTICAL COMPOSITION FORMED BY COMBINING PYRIDOXAMINE COMPOUND AND THIAMINE COMPOUND | SLC19A2, PLPBP, PNPO | TDP1 2163/4885TKT 19/4885LMNA 1955/4885 |
| US-11564924-B2 | Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound | SLC19A2, PLPBP, PNPO | TDP1 2163/4885TKT 19/4885LMNA 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.